Dae Hwa Pharm KRX:067080KOSDAQ
대화제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h4
Articles, 7 days4
DART filings, 7 days1
Articles tracked4since Sep 11
In Q2 2026, Dae Hwa Pharm reported revenue of ₩41.3bn, up 14.8% year on year, and operating profit of ₩3.3bn. Dae Hwa Pharm (대화제약) appeared in 4 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 14 with 2 articles. The most common catalyst was contracts & orders (2).
Dae Hwa Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩41.3bn | +14.8% | ₩3.3bn | ₩2.0bn |
| Q1 2026 | ₩37.0bn | +1.0% | ₩454m | −₩266m |
| Q4 2025 derived | ₩33.7bn | -16.0% | ₩699m | ₩3.3bn |
| Q3 2025 | ₩36.7bn | +2.6% | ₩1.0bn | −₩179m |
| Q2 2025 | ₩36.0bn | -7.3% | ₩285m | −₩517m |
| Q1 2025 | ₩36.7bn | +5.7% | ₩1.1bn | −₩297m |
| Q4 2024 derived | ₩40.1bn | +4.2% | ₩3.4bn | ₩1.4bn |
| Q3 2024 | ₩35.8bn | +1.3% | ₩1.7bn | ₩218m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Dae Hwa Pharm top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
